Immediate Impact
1 from Science/Nature 57 standout
Citing Papers
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
2025 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Works of Malaz Abutarif being referenced
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
2021
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
2009
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Malaz Abutarif | 144 | 78 | 138 | 127 | 33 | 379 | |
| N Brown | 172 | 89 | 66 | 37 | 24 | 457 | |
| A. D. R. Huitema | 131 | 59 | 47 | 32 | 26 | 425 | |
| Ali Nassif | 85 | 31 | 46 | 102 | 26 | 423 | |
| Seok Ho Lee | 94 | 64 | 34 | 72 | 43 | 402 | |
| Pascal Chanu | 133 | 50 | 18 | 98 | 27 | 383 | |
| Tomoyoshi Inoue | 99 | 35 | 52 | 82 | 28 | 439 | |
| A Drochmans | 94 | 68 | 23 | 89 | 19 | 413 | |
| Burchenal Jh | 203 | 71 | 21 | 39 | 37 | 419 | |
| Sujith Kalmadi | 133 | 99 | 81 | 145 | 26 | 399 | |
| Stefania Cheli | 102 | 28 | 41 | 35 | 37 | 420 |
All Works
Loading papers...